Product Code: 596200649
Can prescription barriers help other HIV brands catch up to the runaway market leader?
In the US HIV treatment market, the #1 brand has a 10% market share lead over its nearest rival. Will market barriers be the deciding factor in close races for 2nd and 3rd place?
Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Evotaz, Intelence, Isentress, Selzentry, Stribild, Triumeq, Truvada, and Viread.
You'll find out which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.
Get Answers to Key Questions about HIV Drug Brands
- Evotaz (atazanavir/cobicistat; BMS) : Does Evotaz lose more market share because of pricing or formulary availability?
- Intelence (etravirine; Janssen Biotech) : Does Intelence lose more market share to Isentress or Stribild?
- Isentress (raltegravir; Merck & Co.) : Does Isentress gain more market share when competing brands are too expensive or when they're not available on formularies?
- Selzentry (maraviroc; ViiV Healthcare) : Which market barriers cost Selzentry the most market share. How much share would it gain if they didn't exist?
- Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead) : Do more doctors prescribe Stribild or Triumeq? Which brand has more market share?
- Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare) : Only two FDCs saw a net share gain because of barriers. Is Triumeq one of them?
- Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead) : Is Truvada taking more market share from Stribild or is it the other way 'round?
- Viread (tenofovir disoproxil fumarate; Gilead) : Only one monotherapy saw a net share gain because of barriers. Is it Viread?
- Clear market leader: The most prescribed brand not only has a 12% market share advantage, it also sees twice the barrier-related share gain (net) of its nearest rival.
- Only three brands benefit from barriers: These brands all saw a net gain in market share, while the other five saw net losses.
- Brand awareness is high: 97% or greater among doctors surveyed for any given brand.
- Barrier effect is uneven: The number of doctors who experience the top 3 market barriers varies greatly from brand to brand.
- FDCs somewhat more prescribed: Although nearly all surveyed brands are widely prescribed, three of the four most prescribed brands are fixed-dose combinations.
- Cost barriers have the greatest impact: Barriers related to pricing and formulary availability affect more prescriptions than any others.
- Barrier effect significant for "other" brands: Taken together, "other" brands have a greater market share than 5 of the surveyed brands, and see the third biggest net gain due to barriers.
Exploring Market Access Issues
Market Access Impact: HIV explores key issues affecting HIV drug manufacturers. You'll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest effect?
How barriers affect your brand:
- How many doctors prescribe your brand? How many don't, but would consider it?
- Why don't doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 Medical Oncologists in the US, chosen from the largest community of validated physicians in the world
All respondents have:
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with melanoma in total in the last month
We conducted the survey between March 2nd and 9th, 2016.